Category Archives: Investment

Flood gates for medical IPO filings still wide open as Labor Day holiday only speeds up pace for hopefuls.

The somber mood of summer’s waning days and shortened work week didn’t cool the blistering pace of biotech and other healthcare IPO news. Almost makes me feel sorry for the… Read more »

Weekly Medical Stock Spotlight: 3 big winners and 2 total duds.

1) ProQR Therapeutics NV (Nasdaq:PRQR) led advancing issues on the Labor Day-shortened week, soaring 107% over the week to $15.80 on Friday (August 31, 2018). The upward move came after the… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »

Solution to China’s vaccine scandal now in the hands of rising blockchain maven VeChain. Buy a few tokens?

The News: A new production scandal has undermined Chinese citizens’ confidence in domestically made vaccines, and the tech community is suggesting the solution may lie in a highly touted technology: blockchain…. Read more »

Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

The News: Bexion Pharmaceuticals burst out of the shadows of near total obscurity last week as its investigational cancer treatment, BXQ-350, grabbed plenty of mainstream media coverage as a potential game-changer. BXQ-350 is… Read more »

Move over, Nasdaq: BeiGene’s mammoth IPO in Hong Kong sends message to biotech startups.

The News: Nasdaq-listed Chinese biotech BeiGene Ltd. (Beijing) has raised an astounding $903 million after pricing its secondary listing in Hong Kong–the first under new exchange rules–near the top of… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »

Healthcare IPOs defy gravity and second law of thermodynamics with 8 new pricings last week and 2 new filings.

Well, here we are again, looking back at another massive round of biotech IPOs priced just last week, as the beat goes on and on and… My trusty, hand-held calculator… Read more »

Top 1H health-sector winners and losers; buy/sell opinion.

The News: Now that we’ve reached the end of the first half of 2018, there might be some interesting surprises–both good and not-so-good–for those equity investors interested in who’s being… Read more »

Biotech IPOs smash record in H1, soaking up huge raises from the cash still parked on the sidelines. Will supply of buyers run out, like always?

The News: Last week the Nasdaq Biotech Index swooned 4% on Wednesday (July 27, 2018), only to rebound and halve that downdraft by Friday’s close (July 29, 2018). But despite… Read more »